A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

• Status: RECRUITING
• Trial end date: 2031-08-12

Summary

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

• Phase: PHASE2

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: 130-nm albumin-bound paclitaxel; Carboplatin; Cisplatin; Paclitaxel; pembrolizumab; Pemetrexed